Preventing oxaliplatin-induced neurotoxicity: rationale and design of phase Ib randomized, double-blind, placebo-controlled, cross-over trials for early clinical evaluation of investigational therapeutics. (1st December 2016)

• Record Type: Journal Article
• Authors: Han, Catherine H.; Kilfoyle, Dean H.; Hill, Andrew G.; Jameson, Michael B.; McKeage, Mark J.
• Is Part Of: Expert opinion on drug metabolism and toxicology. Volume 12:Number 12(2016:Dec.)
• Page Start: 1479
• Page End: 1490
• Publication Date: 2016-12-01
• Subjects: Oxaliplatin -- chemotherapy neurotoxicity -- nerve hyperexcitability -- pharmacokinetics -- phase I clinical trial design -- chemoprotection -- crossover trial; Drugs -- Toxicology -- Periodicals; Drugs -- Metabolism -- Periodicals; 615.7
• DOI: 10.1080/17425255.2016.1223625
• Languages: English
• ISSNs: 1742-5255

Abstract

ABSTRACT: Introduction : Oxaliplatin-based chemotherapy has become the standard treatment for colorectal cancer and other gastrointestinal tumor types. Oxaliplatin-induced neurotoxicity is a major treatment-limiting side effect that compromizes the delivery of cancer treatment and causes long-standing neurological deficits that negatively impact upon patient quality of life Areas covered : The prevention of oxaliplatin-induced neurotoxicity represents an important opportunity for new therapeutic product development to address this major unmet medical need. In this article, we describe a phase Ib clinical trial design, and study procedures and protocols, that we have developed and now propose for the early clinical evaluation of investigational therapeutics for preventing oxaliplatin-induced neurotoxicity. Expert opinion : Recently, several advances have been made in the development of research methodologies applicable to the clinical evaluation of investigational drugs for preventing oxaliplatin-induced neurotoxicity. As we gain better understanding of the mechanisms of oxaliplatin-induced neurotoxicity, we will be able to use these methods to develop and test more effective and targeted neuroprotective agents that may not only improve patients' quality of life but also improve treatment delivery and survival outcomes.